Last edition
News about "clinical biopharmaceutical company"
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Trial of AT-587 for Hepatitis E Treatment
Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial evaluating AT-587, an investigational oral antiviral candidate for hepatitis E virus (HEV) infection. The study will assess the drug's safety and pharmacokinetics, supporting the development of a potential new treatment for chronic HEV, particularly in immunocompromised patients.
Clinical Biopharmaceutical Company | 17/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy